WO2017060322A3 - Conjugué anticorps-médicament (adc) inhibiteur de ptefb - Google Patents

Conjugué anticorps-médicament (adc) inhibiteur de ptefb Download PDF

Info

Publication number
WO2017060322A3
WO2017060322A3 PCT/EP2016/073825 EP2016073825W WO2017060322A3 WO 2017060322 A3 WO2017060322 A3 WO 2017060322A3 EP 2016073825 W EP2016073825 W EP 2016073825W WO 2017060322 A3 WO2017060322 A3 WO 2017060322A3
Authority
WO
WIPO (PCT)
Prior art keywords
binder
antibody
antigen
tpp
tweakr
Prior art date
Application number
PCT/EP2016/073825
Other languages
English (en)
Other versions
WO2017060322A2 (fr
Inventor
Pierre Wasnaire
Nils Griebenow
Niels Böhnke
Ulrich LÜCKING
Hans-Georg Lerchen
Beatrix Stelte-Ludwig
Christoph Mahlert
Ulf Bömer
Simone Greven
Lisa Dietz
Carsten TERJUNG
Kunzeng ZHENG
Gao Ping
Gang Chen
Jiajun XI
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of WO2017060322A2 publication Critical patent/WO2017060322A2/fr
Publication of WO2017060322A3 publication Critical patent/WO2017060322A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de nouveaux conjugués d'un liant ou d'un dérivé de celui-ci avec une ou plusieurs molécules d'un composant actif, le composant actif étant un inhibiteur de la kinase CDK9, qui est conjugué au liant par l'intermédiaire d'un lieur Z tel que décrit et défini dans la description. L'invention concerne également des procédés pour leur préparation, leur utilisation pour le traitement et/ou la prophylaxie de troubles, en particulier de troubles d'hyperprolifération.<i />
PCT/EP2016/073825 2015-10-10 2016-10-06 Conjugué anticorps-médicament (adc) inhibiteur de ptefb WO2017060322A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/091643 2015-10-10
CN2015091643 2015-10-10

Publications (2)

Publication Number Publication Date
WO2017060322A2 WO2017060322A2 (fr) 2017-04-13
WO2017060322A3 true WO2017060322A3 (fr) 2017-05-18

Family

ID=57121241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/073825 WO2017060322A2 (fr) 2015-10-10 2016-10-06 Conjugué anticorps-médicament (adc) inhibiteur de ptefb

Country Status (1)

Country Link
WO (1) WO2017060322A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6888000B2 (ja) * 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト 新規な修飾された大環状化合物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3601236A1 (fr) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Nouveaux composés macrocycliques inhibiteurs de ptefb
WO2018177899A1 (fr) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Nouveaux composés macrocycliques inhibiteurs de ptefb
EP3919911A1 (fr) * 2020-06-04 2021-12-08 Urteste S.A. Nouveau marqueur de diagnostic du cancer de la prostate
WO2022175595A1 (fr) * 2021-02-16 2022-08-25 Glykos Finland Oy Charges utiles de lieurs et leurs conjugués
CN113603708B (zh) * 2021-07-27 2023-08-11 中国药科大学 一种具有大环骨架结构的cdk9抑制剂的制备及其应用
WO2023057812A1 (fr) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Composés, compositions pharmaceutiques et méthodes pour le traitement, la prévention ou la gestion d'un trouble hyperprolifératif
WO2023061405A1 (fr) * 2021-10-12 2023-04-20 成都科岭源医药技术有限公司 Conjugué lieur-médicament ciblé hautement stable
WO2024094171A1 (fr) * 2022-11-04 2024-05-10 江苏恒瑞医药股份有限公司 Composé aminopyrimidine substitué, son procédé de préparation et son utilisation médicale

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209895A1 (en) * 2002-08-21 2004-10-21 Schering Ag Macrocyclic pyrimidines, their production and use as pharmaceutical agents
WO2008060248A1 (fr) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Pyrimidines substituées par indole, et leur utilisation dans le traitement d'un cancer
WO2013037896A1 (fr) * 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh 5-fluoropyrimidines disubstituées
WO2013184514A1 (fr) * 2012-06-04 2013-12-12 Irm Llc Méthodes de marquage spécifiques à un site et molécules ainsi produites
WO2014031937A1 (fr) * 2012-08-23 2014-02-27 Virostatics Srl Nouveaux dérivés d'aminopyrimidine à disubstitution 4,6
WO2014150937A1 (fr) * 2013-03-15 2014-09-25 Novartis Ag Conjugués anticorps-médicament
WO2014160160A2 (fr) * 2013-03-13 2014-10-02 Novartis Ag Conjugués anticorps-médicaments
WO2015001021A1 (fr) * 2013-07-04 2015-01-08 Bayer Pharma Aktiengesellschaft Dérivés 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine substitués par un groupe sulfoximine et leur utilisation comme inhibiteurs de la cdk9 kinase

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1307271A (en) 1970-06-25 1973-02-14 Shell Int Research Sulphoximine derivatives and their use in herbicidal compositions
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
DE69032979T2 (de) 1989-10-20 1999-11-04 Medarex Inc Bispezifische heteroantikörper mit zweifachen effektorfunktionen
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ES2129029T5 (es) 1990-10-05 2005-10-16 Celldex Therapeutics, Inc. Inmunoestimulacion dirigida con reactivos biespecificos.
WO1992008802A1 (fr) 1990-10-29 1992-05-29 Cetus Oncology Corporation Anticorps bispecifiques, methodes de production et utilisation desdits anticorps
SK281142B6 (sk) 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
AP257A (en) 1991-04-26 1993-06-03 Surface Active Ltd A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
ES2144440T3 (es) 1992-08-18 2000-06-16 Centro Inmunologia Molecular Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen.
DK0719859T3 (da) 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
CA2229043C (fr) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Banques de proteines/(poly)peptides
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
ATE318147T1 (de) 1996-03-25 2006-03-15 Medarex Inc Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
MXPA02000961A (es) 1999-07-29 2003-08-20 Medarex Inc Anticuerpos monoclonales humanos para antigeno de membrana especifico de la prostata.
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
UA77157C2 (en) 2000-02-25 2006-11-15 Polypeptide anti-egfrviii scfvs with improved cytotoxicity and output, molecule of nucleic acid, that codes the indicated polypeptide, and method of cell destructure with using of this polypeptide
AU2001258567A1 (en) 2000-05-19 2001-11-26 Scancell Limited Humanised antibodies to the epidermal growth factor receptor
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
AU2002334799B2 (en) 2001-04-26 2009-05-07 Biogen Ma Inc. Cripto-specific antibodies
CA2715570A1 (fr) 2001-04-26 2002-11-07 Biogen Idec Ma Inc. Anticorps de blocage cripto et utilisations correspondantes
EP1392359B2 (fr) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Proteines de liaison specifiques et utilisations associees
CA2450285C (fr) 2001-06-13 2016-08-02 Genmab A/S Anticorps monoclonaux humains diriges contre le recepteur de facteur de croissance epidermique (egfr)
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2002356844C1 (en) 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
US7291616B2 (en) 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
MXPA04012656A (es) 2002-06-14 2005-08-15 Immunomedics Inc Anticuerpo hpam4 monoclonal humanizado.
DK2256108T3 (en) 2002-07-18 2016-04-11 Janssen Pharmaceutica Nv Substituted triazinkinaseinhibitorer
JP2006518381A (ja) 2003-02-07 2006-08-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
CA2521594A1 (fr) 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 et troubles cellulaires hyperproliferatifs
AU2004259398A1 (en) 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
JP2007503202A (ja) 2003-07-21 2007-02-22 イミュノジェン・インコーポレーテッド Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法
WO2005026129A1 (fr) 2003-09-15 2005-03-24 Gpc Biotech Ag Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
US20050142133A1 (en) 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP1735348B1 (fr) 2004-03-19 2012-06-20 Imclone LLC Humain anticorps dirige contre le recepteur du facteur de croissance epidermique
EP1819359B1 (fr) 2004-12-09 2015-03-18 Janssen Biotech, Inc. Immunoconjugues anti-integrines, methodes pour leur production et leur application
EP1674470A1 (fr) 2004-12-22 2006-06-28 Schering Aktiengesellschaft Sulfonamide-macrocycles comme Tie2-inhibiteurs
EP1674469A1 (fr) 2004-12-22 2006-06-28 Schering Aktiengesellschaft Sulfonamide-macrocycles comme Tie2-inhibiteurs
EP2230517A1 (fr) 2005-01-07 2010-09-22 Diadexus, Inc. Compositions d'anticorps OVR11 et procédés d'utilisation
JP2008530244A (ja) 2005-02-18 2008-08-07 メダレックス， インク． フコシル残基を欠くｃｄ３０に対するモノクローナル抗体
KR101275609B1 (ko) 2005-03-30 2013-06-19 후지필름 가부시키가이샤 용액 캐스팅 방법
EP1710246A1 (fr) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Macrocycles de sulfoximine-pyrmidine et leurs sels correspondants, leurs procédé de fabrication, et leurs utilisation pharmaceutique contre le cancer
CN103127523A (zh) 2005-06-20 2013-06-05 Psma开发有限公司 Psma抗体-药物缀合物
BRPI0615049B1 (pt) 2005-08-24 2023-04-25 Immunogen, Inc Processo para a preparação de um conjugado de anticorpo- maitansinóide
EA016186B1 (ru) 2005-09-26 2012-03-30 Медарекс, Инк. Человеческие моноклональные антитела к cd70 и их применение
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP1803723A1 (fr) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft Dérivés (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide en tant qu'inhibiteurs de la kinase aurora pour le traitement de cancer
EP1873159A1 (fr) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Sulfonamides macrocycliques substitués et leurs sels comme inhibiteurs Tie2, compositions pharmaceutiques, methodes pour leur pröparation et leurs utilisations
EP1870416A1 (fr) 2006-06-21 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Macrocycles du type sulfonamide en tant qu'inhibiteurs de la Tie2
WO2008004834A1 (fr) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Anticorps monoclonal humanisé à forte liaison au récepteur de facteur de croissance épidermique, récepteur egf
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
EP2066349B1 (fr) 2006-09-08 2012-03-28 MedImmune, LLC Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes
EP1911766A1 (fr) 2006-10-13 2008-04-16 Glycotope Gmbh Utilisation des cellules humaines provenant d'une leucémie myéloide pour l'expression d'anticorps
EP1900750A1 (fr) 2006-09-18 2008-03-19 Glycotope Gmbh Système de production à haut rendement, entièrement humain, pour anticorps améliorés
PT2073842E (pt) 2006-09-10 2015-04-07 Glycotope Gmbh Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
WO2008036688A2 (fr) 2006-09-18 2008-03-27 Xencor, Inc. Anticorps optimisés ciblant l'antigène hm1.24
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
EP2094682A2 (fr) 2006-12-22 2009-09-02 Novartis AG Composés organiques et leurs utilisations
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
MX2009009792A (es) 2007-03-12 2009-09-23 Cytopia Res Pty Ltd Compuestos de fenil amino pirimidina y usos de los mismos.
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
US8507498B2 (en) 2007-04-24 2013-08-13 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
JP5693951B2 (ja) 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
EP2545938A1 (fr) 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Utilisation thérapeutique dýanticorps de récepteur anti-TWEAK
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
CA2698511C (fr) 2007-09-04 2016-10-11 The Scripps Research Institute Pyrimidinyl-amines substituees en tant qu'inhibiteurs de la proteine kinase
WO2009033094A2 (fr) 2007-09-07 2009-03-12 Agensys, Inc. Anticorps et molécules apparentées qui se lient aux protéines 24p4c12
US8039597B2 (en) 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
AU2008329221B2 (en) 2007-11-26 2013-11-07 Bayer Intellectual Property Gmbh Anti-mesothelin antibodies and uses therefor
PL2242772T3 (pl) 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
ES2475201T3 (es) 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
PL2247304T3 (pl) 2008-04-02 2017-01-31 Macrogenics, Inc. Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
JP2011518836A (ja) 2008-04-24 2011-06-30 インサイト・コーポレイション 大環状化合物およびそれらのキナーゼ阻害剤としての使用
AU2009246640A1 (en) 2008-05-15 2009-11-19 Biogen Idec Ma Inc. Anti-Fn14 antibodies and uses thereof
AU2009271019A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
KR101706255B1 (ko) 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
CN102325549A (zh) 2009-03-31 2012-01-18 罗氏格黎卡特股份公司 用人源化抗-EGFR IgG1抗体和伊立替康治疗癌症
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
WO2011026917A1 (fr) 2009-09-04 2011-03-10 Novartis Ag Composés d'hétéroaryle en tant qu'inhibiteurs de kinase
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
RU2583298C2 (ru) 2009-10-07 2016-05-10 Макродженикс, Инк. ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU2010306927A1 (en) 2009-10-12 2012-05-31 Myrexis, Inc. Amino - pyrimidine compounds as inhibitors of TBKL and/or IKK epsilon
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
ES2619585T3 (es) 2010-03-22 2017-06-26 Lead Discovery Center Gmbh Derivados de triazina disustituidos farmacéuticamente activos
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
JP2013542967A (ja) 2010-11-17 2013-11-28 ノバルティス アーゲー ３−（アミノアリール）−ピリジン化合物
WO2012066065A1 (fr) 2010-11-17 2012-05-24 Novartis Ag Composés phényl-hétéroaryl amine et leurs utilisations
WO2012101066A1 (fr) 2011-01-28 2012-08-02 Novartis Ag Composés de pyridine biarylamine et utilisation de ceux-ci
WO2012101064A1 (fr) 2011-01-28 2012-08-02 Novartis Ag Composés à base de n-acyl-pyrimidine-biaryl convenant comme inhibiteurs de protéine kinase
CN103339110A (zh) 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
WO2012101063A1 (fr) 2011-01-28 2012-08-02 Novartis Ag Composés de n-acyl pyridine biaryl et leurs utilisations
WO2012101065A2 (fr) 2011-01-28 2012-08-02 Novartis Ag Composés de pyrimidine biarylamine et leurs utilisations
US9242937B2 (en) 2011-03-02 2016-01-26 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted pyridine derivatives
US9226929B2 (en) 2011-03-02 2016-01-05 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
US20140288044A1 (en) 2011-04-12 2014-09-25 Alzheimer's Institute Of America, Inc. Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors
CN102731413A (zh) 2011-04-15 2012-10-17 上海医药工业研究院 一种脲类化合物、其制备方法、其中间体及其应用
US8916557B2 (en) 2011-04-19 2014-12-23 Bayer Intellectual Property Gmbh Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines
US20140127240A1 (en) 2011-04-21 2014-05-08 Bayer Pharma Aktiengesellschaft Novel Binder-Drug Conjugates (ADCs) and Use of Same
KR101972303B1 (ko) 2011-06-10 2019-04-25 메르사나 테라퓨틱스, 인코포레이티드 단백질-중합체-약물 접합체
WO2013037894A1 (fr) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Dérivés de 5-fluoropyrimidine disubstitués contenant un groupe sulfoximine
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
CN105283453B (zh) 2012-10-18 2018-06-22 拜耳药业股份公司 含砜基的n-(吡啶-2-基)嘧啶-4-胺衍生物
EP2909176B1 (fr) 2012-10-18 2016-07-20 Bayer Pharma Aktiengesellschaft Derives de n-(pyridin-2-yl)pyridin-2-amine contenant un group sulfone
EP2909183B1 (fr) 2012-10-18 2016-08-24 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophényl-5-fluoropyrimidin-2-yl amines contenant un groupe sulfone
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
NZ707084A (en) 2012-11-15 2019-09-27 Bayer Pharma AG 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
WO2014076028A1 (fr) 2012-11-15 2014-05-22 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophényl)-5-fluoropyrimidin-2-yl amines contenant un groupe sulfoximine
US20150368209A1 (en) 2013-01-07 2015-12-24 École Polytechnique Fédérale De Lausanne (Epfl) 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections
TW201437211A (zh) 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
CA2915311A1 (fr) 2013-06-14 2014-12-18 Bayer Pharma Aktiengesellschaft Anticorps anti-tweakr et leurs utilisations
CA2942119A1 (fr) 2014-03-13 2015-09-17 Bayer Pharma Aktiengesellschaft Derives 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine contenant un groupe sulfone

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209895A1 (en) * 2002-08-21 2004-10-21 Schering Ag Macrocyclic pyrimidines, their production and use as pharmaceutical agents
WO2008060248A1 (fr) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Pyrimidines substituées par indole, et leur utilisation dans le traitement d'un cancer
WO2013037896A1 (fr) * 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh 5-fluoropyrimidines disubstituées
WO2013184514A1 (fr) * 2012-06-04 2013-12-12 Irm Llc Méthodes de marquage spécifiques à un site et molécules ainsi produites
WO2014031937A1 (fr) * 2012-08-23 2014-02-27 Virostatics Srl Nouveaux dérivés d'aminopyrimidine à disubstitution 4,6
WO2014160160A2 (fr) * 2013-03-13 2014-10-02 Novartis Ag Conjugués anticorps-médicaments
WO2014150937A1 (fr) * 2013-03-15 2014-09-25 Novartis Ag Conjugués anticorps-médicament
WO2015001021A1 (fr) * 2013-07-04 2015-01-08 Bayer Pharma Aktiengesellschaft Dérivés 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine substitués par un groupe sulfoximine et leur utilisation comme inhibiteurs de la cdk9 kinase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G. NEMETH ET AL: "Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection", CURRENT MEDICINAL CHEMISTRY, vol. 18, no. 3, 1 January 2011 (2011-01-01), pages 342 - 358, XP055117496, ISSN: 0929-8673, DOI: 10.2174/092986711794839188 *
MEADE B R ET AL: "Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides", ADVANCED DRUG DELIVERY REVIEWS, vol. 59, no. 2-3, 30 March 2007 (2007-03-30), pages 134 - 140, XP002609883, ISSN: 0169-409X, DOI: 10.1016/J.ADDR.2007.03.004 *
RITA NAHTA ET AL: "Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer", CANCER RESEARCH, vol. 63, no. 13, 1 July 2003 (2003-07-01), US, pages 3626 - 3631, XP055361817, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2017060322A2 (fr) 2017-04-13

Similar Documents

Publication Publication Date Title
WO2017060322A3 (fr) Conjugué anticorps-médicament (adc) inhibiteur de ptefb
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
JP2017149720A5 (fr)
EA201891066A1 (ru) Антитела к ror1
WO2016191246A3 (fr) Anticorps semblables aux récepteurs de lymphocytes t spécifiques pour un peptide prame
JP2018501197A5 (fr)
MX2020012567A (es) Anticuerpos anti-ox40 y metodos de uso.
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
WO2012135854A3 (fr) Anticorps contre des peptides cytosoliques
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
MX2009010120A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
RU2016100892A (ru) Антитела против tweakr и их применение
HRP20150934T1 (hr) Djelovanje na abcb5 u terapiji raka
RU2015144105A (ru) Антитела к гепсидину и их применения
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
MX2022005850A (es) Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16778787

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16778787

Country of ref document: EP

Kind code of ref document: A2